Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer - Test2 - elhamkhani - TriplyDB

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

http://www.wikidata.org/entity/Q29616236

about

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer Markers of resistance to anti-EGFR therapy in colorectal cancer The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-α-1,3-galactose Molecular origins of cancer: Molecular basis of colorectal cancer Phase I/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer.Adding pharmacogenomics to the development of new marine-derived anticancer agents Mechanisms of drug resistance in colon cancer and its therapeutic strategies Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options New trends in molecular and cellular biomarker discovery for colorectal cancer Current targeted therapies in the treatment of advanced colorectal cancer: a review Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer Molecular testing to optimize therapeutic decision making in advanced colorectal cancer Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib Biomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRAS Pharmacologic resistance in colorectal cancer: a review Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer Clinical efficacy and drug resistance of anti-epidermal growth factor receptor therapy in colorectal cancer Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer Tumor evolution and intratumor heterogeneity in colorectal carcinoma: insights from comparative genomic profiling of primary tumors and matched metastases Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer Adjuvant chemotherapy for rectal cancer: Is it needed?Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review The Insulin/IGF System in Colorectal Cancer Development and Resistance to Therapy Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis The role of Reg IV in colorectal cancer, as a potential therapeutic target Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

P2860

Q21142734-5A6DF45B-F468-4354-9D74-5BF52D559FF4 Q21198850-B7408669-4D01-47FE-8281-43CBFC14758D Q24243806-A84828BE-A103-4829-BC52-438173E8B12A Q24563539-368F0793-5715-44EC-8206-154034E10C33 Q24598640-BF5769CF-E086-4952-A398-FAA2B138BAF3 Q24604244-2368D803-7374-41CD-B286-A1252D078388 Q24617331-48BB5B29-4551-4BEB-ACB7-270DDBEFBC60 Q24633957-6F745441-1F54-4519-B996-7583B0535D83 Q24646343-9B2BFB62-8846-4A26-A585-0B2F1BF8BCAE Q24647888-9A8763E9-5324-4B51-86A7-CC37ED48FE03 Q24649684-C5B43D3C-E181-4117-926E-6722D947B6D6 Q24651894-1B8722AC-DB02-42A4-B69E-AC20C94FAE37 Q24652337-08A84EBF-05D5-4B11-999C-E4BD49270161 Q24675853-AD687FA4-1A88-4138-9DF5-BB76D2B88ADA Q24811929-5ED8AFAB-AAED-4266-A79F-4DD6787751D8 Q24812583-D2A4BB1A-2B17-418F-A69A-3479DF907F09 Q25254985-77632666-E649-49FA-AB6B-CF1ECEBCA4BF Q26738528-9D4F889F-0945-45EB-BC73-786433CB2E28 Q26738655-DEA49592-25BB-4940-8780-9540470D6269 Q26739049-DCE61E63-CFA4-4210-B8E0-7C7EDFC9794D Q26740067-2ED90085-07F1-4184-AD82-7A8D6D0AD979 Q26748924-539BA48D-E9A7-476F-9EE9-AF9427C7815E Q26749012-573D56C0-0982-4307-9E0E-570B1436389C Q26751344-DCE7AA97-011F-466F-B115-7E842CF255AC Q26765210-EACF5F32-715F-4CC5-8B61-23A32F757FDA Q26766535-FC6B27B1-B4BB-4EF3-AA86-409181E80582 Q26769850-ABA4EC25-E228-4170-895A-91BC216F379E Q26769884-AA684970-8E56-4E58-A81A-DC5045B114CD Q26769935-8A14BB20-E87C-4D83-B7B4-9524A6C868D6 Q26769958-CD14A90E-CA62-4B42-851D-1F0AC92FF84E Q26772267-D531C102-9D06-4623-A87F-83B60DAEBB39 Q26772274-B52D76FC-790C-404C-8F31-02790B874FFD Q26774605-164CA03D-D562-45B3-8A1F-4C2EAF450B16 Q26775099-6B6E92B9-ADAE-4246-B62E-82E08FCB12C3 Q26775522-54861E17-5FFE-4E7D-8F33-9B10E737A4E8 Q26777125-21992AE8-188B-4274-82FB-C42C5B9BACDA Q26777704-E7507670-7486-4AB8-B9CE-DF9551794876 Q26777750-70A71368-6652-4C55-99F8-6C49ECF6CEF0 Q26783895-1FE52FAB-898C-4D95-924C-2D50D472BFF9 Q26796348-18C2F150-ADA4-41E4-A628-54001B8F8B5C

P2860

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

http://www.wikidata.org/entity/Q29616236

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@ast

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@en

type

label

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@ast

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@en

prefLabel

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@ast

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@en

P1433

Q29616236-DB1C229C-DC3B-4904-809E-F814368A269B

P1476

Q29616236-7D399C36-0384-4F8B-AD0C-7049D9A32DAA

P2093

Q29616236-1124D660-244E-4D51-AD63-8F09A1B21B53

Q29616236-1BD2C4A0-B6A1-4B8C-8CE9-8399BA6CA1E0

Q29616236-3529FD5B-6B3F-4469-8E36-5ABFB98E949A

Q29616236-5B17D89B-109E-4068-A979-8A8BC45BBEB6

Q29616236-A411E90D-8C54-4893-9E17-812800180757

Q29616236-AC939211-3A9E-4DD0-9EC0-2FA959F5A25A

Q29616236-AE08061A-166E-4923-A97E-DE987B335E63

Q29616236-E63DCD75-D998-48DE-B916-25FC0CE7F9A2

Q29616236-EBA90646-DEF8-4946-BCD5-2D94FD21EDD8

Q29616236-FE9C8EB1-0179-4EBB-9C22-6E3A9191ED20

P304

Q29616236-F4F77FDD-2523-46A5-ADD5-1917B5B7C682

P31

Q29616236-6843C46A-5132-4044-85B1-4AB86CCF39A4

P3181

Q29616236-EABDD223-04AA-4CB3-A010-39B843F61B41

P356

Q29616236-29E343D5-C8EC-4633-A790-C8553B787543

P407

Q29616236-AC3C8932-695A-45AF-9921-D9BB6E7707C2

P433

Q29616236-F897C06A-F21D-4A68-94B9-07E4B5CEA656

P478

Q29616236-7E1981E3-8E90-4172-846A-2D10B3BE5B91

P50

Q29616236-4B414B46-B308-4AEA-A774-2BA7EB2A1EA9

Q29616236-936EA78C-684B-4650-8F2E-EF98318FD848

P577

Q29616236-4ACC18A8-34FE-4022-B7A3-E992E70E68D7

P698

Q29616236-687DDBB9-414F-4C17-8E2F-06EED9CA0B7F

P921

Q29616236-1AED429F-3DEF-4709-A781-374472E76132

Q29616236-CCE839C9-7AE9-46D5-9434-03CD5DA295A7

P3181

P356

P1433

The New England Journal of Medicine

P1476

Cetuximab monotherapy and cetu ...... y metastatic colorectal cancer

@en

P2093

Andreas Harstrick

http://www.w3.org/2001/XMLSchema#string

Armando Santoro

http://www.w3.org/2001/XMLSchema#string

Chris Verslype

http://www.w3.org/2001/XMLSchema#string

Danny Bets

http://www.w3.org/2001/XMLSchema#string

David Khayat

http://www.w3.org/2001/XMLSchema#string

Eric Van Cutsem

http://www.w3.org/2001/XMLSchema#string

Harry Bleiberg

http://www.w3.org/2001/XMLSchema#string

Ian Chau

http://www.w3.org/2001/XMLSchema#string

Matthias Mueser

http://www.w3.org/2001/XMLSchema#string

Yves Humblet

http://www.w3.org/2001/XMLSchema#string

P304

337-345

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

254067

http://www.w3.org/2001/XMLSchema#string

P356

10.1056/NEJMOA033025

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

David Cunningham

Salvatore Siena

P577

2004-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15269313

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer